ArticleJournal of advanced research2026
Burden profiles and mortality-attributable risk factors for gastrointestinal cancers: A comprehensive analysis, 1990-2021.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Lactobacillus salivarius potentiates gastrointestinal cancer immunotherapy through its metabolite chenodeoxycholic acid.Cell reports. Medicine · 2026Article
- Global burden and trends of tracheal, bronchus, and lung cancer in adolescents and young adults: a secondary analysis of the Global Burden of Disease Study 2021.Journal of thoracic disease · 2026Article
- Review
- CALB2 mediates tumor progression and immune escape in colorectal cancer by shaping an inhibitory immune microenvironment.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrointestinal (GI) cancers accounted for 23.6% of new cancer cases and 34.2% of cancer-related deaths globally. A comprehensive understanding of GI cancer burden and mortality-attributable risk factors is urgently needed.
objectivesWe aim to identify high-risk regions and populations to inform targeted interventions and evidence-based policies for global GI cancer control.
methodsCases, disability-adjusted life years (DALYs), and age-standardized rates (ASRs) were obtained from the Global Burden of Disease Study (GBD) 2021. The socio-demographic index (SDI) was employed to categorize regions. Joinpoint regression was used to assess temporal trends. Risk factor contributions were calculated via the comparative risk assessment framework.
resultsIn 2021, GI cancers caused an estimated 5,255,409 (95% UI: 4,687,432-5,801,303) new cases, 3,698,636 (95% UI: 3,291,859-4,091,466) deaths, and 88,123,735 (95% UI: 79,029,696-97,844,204) DALYs. Regionally, nearly half of the cases and deaths occurred in East Asia and high-income Asia Pacific. Older adults (>65 years) and males bore a significantly greater burden across most GI cancer types. Colorectal cancer and stomach cancer were the major contributors to the burden of GI cancer. Risk-attributable mortality varied by cancer type, region, SDI level, sex, and age. Tobacco use and high body mass index (BMI) were pervasive cross-cancer risk factors. Tobacco use accounted for 11.29% (95% UI: 9.36-13.28) of stomach cancer deaths and 40.64% (95% UI: 33.64-47.05) of esophageal cancer deaths, whereas high BMI contributed to 9.51% (95% UI: 4.07-14.81) of colorectal cancer deaths and 11.69% (95% UI: 8.27-15.59) of gallbladder and biliary tract cancer deaths.
conclusionGI cancers impose a major yet unequal global burden, disproportionately affecting males, older adults, and populations in East Asia. The varying risk patterns underscore the necessity of targeted, region-specific public health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.